Muriel M. Liberto, PhD, Esq., Member, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to Speak at TKG’s Patent Protection for Pharma and Biotechnology in 2017
New York, NY, July 11, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Muriel M. Liberto, PhD, Esq., Member, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. will speak at The Knowledge Group’s webcast entitled: “Patent Protection for Pharma and Biotechnology in 2017 Live Webcast.” This event is scheduled for Wednesday, July 19, 2017 @ 3:00 PM to 5:00 PM (ET). For more information, you can check the event homepage here: https://www.theknowledgegroup.org/webcasts/legal/intellectual-property-law/patent-protection-for-pharma-and-biotechnology-in-2017-live-webcast
About Muriel M. Liberto, PhD, Esq.,
Muriel received her law degree magna cum laude from Fordham University in New York City. Prior to law school, Muriel earned an undergraduate degree in chemistry from the College of William and Mary in Williamsburg, Virginia, and a doctorate in biochemistry from The Ohio State University in Columbus, Ohio.
Muriel’s practice focuses on helping her clients develop patent strategies that maximize strategic value. Her clients feature innovators in the health care industry who are developing molecular diagnostic tools and techniques, platforms for drug delivery, and new therapeutic agents based on both organic small molecules and biologics. In addition to patent drafting, procurement, and portfolio management, Muriel provides counseling on patentability, patent landscape, and freedom to operate. Working with the Mintz Levin team, Muriel also ensures that clients’ IP related interests are well represented and protected in typical transactions, such as confidentiality, materials transfer, licensing, and research collaboration agreements, as well as in financings and acquisitions.
About Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz Levin is ranked among the nation’s leading life sciences law firms and represents companies of all sizes and at all stages of growth, including those operating at the cutting-edge of the biotechnology, pharmaceutical, and medical device industries. The firm provides full-service prosecution and counseling services to assist clients at all stages of the life cycle with their intellectual property needs, from developing IP strategy to executing, managing, and enforcing that strategy worldwide. Mintz Levin’s patent team assesses the patentability, freedom-to-operate, and non-infringement positions of client innovations; determines whether competitor products or patents infringe clients’ patent rights and develops and executes strategies to respond; negotiates licensing agreements and financial transactions; and defends clients’ IP positions with litigation, mediation or arbitration.
Event Synopsis:
The Pharma and Biotechnology industries have been affected by the recent uptakes and patent rejections of the US Patent and Trademark Office (USPTO). Following the release of memorandum on Preliminary Examination Instructions in light of Alice Corp last 2014, the USPTO has been stricter in granting patent eligibility under §101. The office has begun issuing Alice rejections where no previous 101 patent eligibility rejection stood, and these included pharma- and biotech-related patents.
Because of the continued impact of the rejections, it is important to know how pharma and biotechnology industries should gear up for patent protection. In this live webcast, a panel of distinguished professionals and thought leaders will help pharma and biotech professionals understand the important aspects of this significant topic. They will provide an in-depth discussion of patent protection for pharma and biotechnology in 2017. Speakers will also offer best practices in developing and implementing a strategic guide for the pharma and biotech industries in order to overcome possible rejections.
Some of the major topics that will be covered in this course are:
· Overview of significant life sciences Federal Circuit decisions post-Alice
· Update on legislative proposals to amend Section 101
· 101 issues involving abstract ideas and laws of nature in diagnostic methods and related claims
· 101 issues involving products of nature
· Strategies for dealing with and preventing Section 101 rejections
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
About Muriel M. Liberto, PhD, Esq.,
Muriel received her law degree magna cum laude from Fordham University in New York City. Prior to law school, Muriel earned an undergraduate degree in chemistry from the College of William and Mary in Williamsburg, Virginia, and a doctorate in biochemistry from The Ohio State University in Columbus, Ohio.
Muriel’s practice focuses on helping her clients develop patent strategies that maximize strategic value. Her clients feature innovators in the health care industry who are developing molecular diagnostic tools and techniques, platforms for drug delivery, and new therapeutic agents based on both organic small molecules and biologics. In addition to patent drafting, procurement, and portfolio management, Muriel provides counseling on patentability, patent landscape, and freedom to operate. Working with the Mintz Levin team, Muriel also ensures that clients’ IP related interests are well represented and protected in typical transactions, such as confidentiality, materials transfer, licensing, and research collaboration agreements, as well as in financings and acquisitions.
About Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz Levin is ranked among the nation’s leading life sciences law firms and represents companies of all sizes and at all stages of growth, including those operating at the cutting-edge of the biotechnology, pharmaceutical, and medical device industries. The firm provides full-service prosecution and counseling services to assist clients at all stages of the life cycle with their intellectual property needs, from developing IP strategy to executing, managing, and enforcing that strategy worldwide. Mintz Levin’s patent team assesses the patentability, freedom-to-operate, and non-infringement positions of client innovations; determines whether competitor products or patents infringe clients’ patent rights and develops and executes strategies to respond; negotiates licensing agreements and financial transactions; and defends clients’ IP positions with litigation, mediation or arbitration.
Event Synopsis:
The Pharma and Biotechnology industries have been affected by the recent uptakes and patent rejections of the US Patent and Trademark Office (USPTO). Following the release of memorandum on Preliminary Examination Instructions in light of Alice Corp last 2014, the USPTO has been stricter in granting patent eligibility under §101. The office has begun issuing Alice rejections where no previous 101 patent eligibility rejection stood, and these included pharma- and biotech-related patents.
Because of the continued impact of the rejections, it is important to know how pharma and biotechnology industries should gear up for patent protection. In this live webcast, a panel of distinguished professionals and thought leaders will help pharma and biotech professionals understand the important aspects of this significant topic. They will provide an in-depth discussion of patent protection for pharma and biotechnology in 2017. Speakers will also offer best practices in developing and implementing a strategic guide for the pharma and biotech industries in order to overcome possible rejections.
Some of the major topics that will be covered in this course are:
· Overview of significant life sciences Federal Circuit decisions post-Alice
· Update on legislative proposals to amend Section 101
· 101 issues involving abstract ideas and laws of nature in diagnostic methods and related claims
· 101 issues involving products of nature
· Strategies for dealing with and preventing Section 101 rejections
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories